AR090605A1 - Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer - Google Patents
Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- AR090605A1 AR090605A1 ARP130101105A ARP130101105A AR090605A1 AR 090605 A1 AR090605 A1 AR 090605A1 AR P130101105 A ARP130101105 A AR P130101105A AR P130101105 A ARP130101105 A AR P130101105A AR 090605 A1 AR090605 A1 AR 090605A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- alzheimer
- treatment
- receiver antagonist
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta descripción se refiere a métodos de uso de la 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida en una terapia modificadora de la enfermedad para la enfermedad de Alzheimer, otras tauopatías y enfermedades neurodegenerativas relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305415.7A EP2647377A1 (en) | 2012-04-06 | 2012-04-06 | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
US201361792635P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090605A1 true AR090605A1 (es) | 2014-11-26 |
Family
ID=46001073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101105A AR090605A1 (es) | 2012-04-06 | 2013-04-04 | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer |
Country Status (17)
Country | Link |
---|---|
US (2) | US20150031893A1 (es) |
EP (2) | EP2647377A1 (es) |
JP (1) | JP6143842B2 (es) |
KR (1) | KR20150000490A (es) |
CN (1) | CN104363911A (es) |
AR (1) | AR090605A1 (es) |
AU (1) | AU2013244928B2 (es) |
BR (1) | BR112014024736A2 (es) |
CA (1) | CA2868481A1 (es) |
ES (1) | ES2618924T3 (es) |
MX (1) | MX354020B (es) |
PL (1) | PL2833887T3 (es) |
RU (1) | RU2014144615A (es) |
SG (2) | SG10201801200PA (es) |
TW (1) | TW201402119A (es) |
UY (1) | UY34734A (es) |
WO (1) | WO2013150150A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
CN114053289B (zh) * | 2020-08-06 | 2023-06-27 | 北京箭牧科技有限公司 | 瑞德西韦在制备预防和治疗神经***退行性疾病药物中的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1379493A2 (en) | 2001-03-23 | 2004-01-14 | Eli Lilly and Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
WO2004037800A1 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
EP1572215B1 (en) | 2002-12-20 | 2009-09-02 | Glaxo Group Limited | Benzo[d]azepine derivatives for the treatment of neurological disorders |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20060293298A1 (en) | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
DK1615909T3 (da) | 2003-04-23 | 2008-11-17 | Glaxo Group Ltd | Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme |
TW200514781A (en) | 2003-07-18 | 2005-05-01 | Glaxo Group Ltd | Novel compounds |
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
KR100848747B1 (ko) | 2004-03-01 | 2008-07-25 | 액테리온 파마슈티칼 리미티드 | 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
GB0408083D0 (en) | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
PE20060302A1 (es) | 2004-06-18 | 2006-04-08 | Glaxo Group Ltd | Derivados de benzazepina como antagonistas del receptor h3 |
GB0418267D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
WO2006040192A1 (en) | 2004-10-15 | 2006-04-20 | Glaxo Group Limited | Pyrrolidine derivatives as histamine receptors ligands |
KR20070091007A (ko) | 2004-12-07 | 2007-09-06 | 글락소 그룹 리미티드 | 인데닐 유도체 및 신경계 장애의 치료를 위한 이들의 용도 |
WO2006097691A1 (en) | 2005-03-14 | 2006-09-21 | Glaxo Group Limited | Fused thiazole derivatives having affinity for the histamine h3 receptor |
GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
EP1790646A1 (fr) | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
ATE509636T1 (de) | 2006-06-23 | 2011-06-15 | Esteve Labor Dr | Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität |
CL2008000597A1 (es) | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
US20090170869A1 (en) | 2007-09-06 | 2009-07-02 | Desmond John Best | Piperazine derivative having affinity for the histamine h3 receptor |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
EP2328587A1 (en) | 2008-08-29 | 2011-06-08 | Glaxo Group Limited | Dosage form comprising 1-isopropyl-4-{ [4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine or a salt thereof |
WO2010026113A1 (en) * | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
MX2011012824A (es) | 2009-06-26 | 2012-01-27 | Sanofi Sa | Nuevas sales de fumarato de un antagonista del receptor de histamina h3. |
AR077859A1 (es) | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
WO2011051423A1 (en) | 2009-11-02 | 2011-05-05 | Glaxo Group Limited | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
FR2976286B1 (fr) | 2011-06-08 | 2013-05-24 | Servier Lab | 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
EP2745876A1 (en) | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
-
2012
- 2012-04-06 EP EP12305415.7A patent/EP2647377A1/en not_active Ceased
-
2013
- 2013-04-03 TW TW102112006A patent/TW201402119A/zh unknown
- 2013-04-04 AR ARP130101105A patent/AR090605A1/es unknown
- 2013-04-05 MX MX2014011992A patent/MX354020B/es active IP Right Grant
- 2013-04-05 SG SG10201801200PA patent/SG10201801200PA/en unknown
- 2013-04-05 KR KR1020147029735A patent/KR20150000490A/ko not_active Application Discontinuation
- 2013-04-05 AU AU2013244928A patent/AU2013244928B2/en not_active Ceased
- 2013-04-05 WO PCT/EP2013/057241 patent/WO2013150150A1/en active Application Filing
- 2013-04-05 EP EP13714652.8A patent/EP2833887B1/en not_active Not-in-force
- 2013-04-05 ES ES13714652.8T patent/ES2618924T3/es active Active
- 2013-04-05 UY UY0001034734A patent/UY34734A/es not_active Application Discontinuation
- 2013-04-05 RU RU2014144615A patent/RU2014144615A/ru unknown
- 2013-04-05 PL PL13714652T patent/PL2833887T3/pl unknown
- 2013-04-05 SG SG11201406093VA patent/SG11201406093VA/en unknown
- 2013-04-05 CN CN201380029300.6A patent/CN104363911A/zh active Pending
- 2013-04-05 CA CA2868481A patent/CA2868481A1/en not_active Abandoned
- 2013-04-05 JP JP2015503896A patent/JP6143842B2/ja not_active Expired - Fee Related
- 2013-04-05 BR BR112014024736A patent/BR112014024736A2/pt not_active IP Right Cessation
-
2014
- 2014-10-03 US US14/506,089 patent/US20150031893A1/en not_active Abandoned
-
2015
- 2015-10-01 US US14/872,812 patent/US9789102B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BR112014024736A2 (pt) | 2017-07-11 |
CN104363911A (zh) | 2015-02-18 |
EP2833887B1 (en) | 2016-12-28 |
RU2014144615A (ru) | 2016-05-27 |
SG11201406093VA (en) | 2014-10-30 |
EP2647377A1 (en) | 2013-10-09 |
JP2015516963A (ja) | 2015-06-18 |
TW201402119A (zh) | 2014-01-16 |
ES2618924T3 (es) | 2017-06-22 |
CA2868481A1 (en) | 2013-10-10 |
AU2013244928A1 (en) | 2014-10-30 |
MX354020B (es) | 2018-02-08 |
SG10201801200PA (en) | 2018-04-27 |
MX2014011992A (es) | 2015-05-08 |
UY34734A (es) | 2013-11-29 |
WO2013150150A1 (en) | 2013-10-10 |
PL2833887T3 (pl) | 2017-06-30 |
KR20150000490A (ko) | 2015-01-02 |
AU2013244928B2 (en) | 2017-08-10 |
EP2833887A1 (en) | 2015-02-11 |
JP6143842B2 (ja) | 2017-06-07 |
US20160101099A1 (en) | 2016-04-14 |
US20150031893A1 (en) | 2015-01-29 |
US9789102B2 (en) | 2017-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268974B (en) | Labeled inhibitors of prostate-specific membrane antigen (psma), their use as imaging agents and as pharmaceutical agents for the treatment of prostate cancer | |
CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
UA107827C2 (en) | Antibody cd40 | |
EA201391351A1 (ru) | Способы повышения эффективности folr1 терапии рака | |
CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
ZA201700671B (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
PH12016502353A1 (en) | Pharmaceutical composition | |
PT4095130T (pt) | Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata | |
CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
CL2012001293A1 (es) | Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer | |
TW201613577A (en) | Pharmaceutical combinations | |
SG11201601306QA (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
AR090605A1 (es) | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer | |
DK3402537T3 (da) | Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII | |
CO6480943A2 (es) | Nuevas sales de fumarato de un antagonista del receptor de histamina h3 | |
EA201490938A1 (ru) | Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем | |
IT201600128780A1 (it) | Bastoncino igienico per la cura della persona,in particolare per l’igiene dell’orecchio | |
EA201491226A1 (ru) | НОВОЕ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ p75 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |